The effect of duration of treatment with valganciclovir in children with renal transplantatio

Not Applicable

• Conditions: Condition 1: renal failure. Condition 2: CMV infection.; Acute renal failure; Other and unspecified infectious diseases

• Registration Number: IRCT2015021321062N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 86

Inclusion Criteria

The children who receive organs from people who are CMV positive; The children are 1-14 years-old
Exclusion criteria: The use of Thymoglobuline drug; The children who are effected severely by side effects of valganciclovir drug; for example: severe leukopenia or anemia

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CMV infection. Timepoint: before intervention, 15 days after intervention, every month until 1 year after intervention. Method of measurement: Laboratory methods of Qualitit PCR and PP65.

Secondary Outcome Measures

Name	Time	Method
Side effects of valganciclovir drug like: Anemia and Allergic hypersensitivity. Timepoint: every month after intervention until 1 year. Method of measurement: clinical presentation.